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Background: Azithromycin treatment improves clinical parameters in patients with CF, and alters macrophage activation from a pro-inﬂammatory
(M1) phenotype to a pro-ﬁbrotic, alternatively activated (M2) phenotype. The transcriptional proﬁle of cells from patients receiving azithromycin
is unknown.
Methods: Gene expression in association with macrophage polarization, inﬂammation, and tissue remodeling was assessed from sputum samples
collected from patients with CF. Transcriptional proﬁles and clinical characteristics, including azithromycin therapy, were compared.
Results: Expression of NOS2 and TNFα was decreased in subjects receiving azithromycin, whereas expression of M2-associated genes was
unaffected. Principal component analysis revealed gene expression proﬁles consistent with M1- (MMP9, NOS2, and TLR4) or M2-polarization
(CCL18, ﬁbronectin, and MR1) in select subject groups. These expression signatures did not signiﬁcantly correlate with clinical characteristics.
Conclusions: Pro-inﬂammatory gene expression was low in subjects receiving AZM. Genes were stratiﬁed into groupings characteristic of M1- or
M2-polarization, suggesting that overall polarization status is distinct among patient groups.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Macrophage phenotype; Cystic ﬁbrosis; Azithromycin1. Introduction
Patients with cystic fibrosis (CF) endure a progressive pul-
monary pathology governed by a chronic, exaggerated inflam-
matory response [1]. Defects in the cystic fibrosis transmembrane
regulator (CFTR) gene result in lungs with thickened mucus that⁎ Corresponding author at: University of Kentucky College of Pharmacy, 789
S. Limestone St., Room 231, Lexington, KY 40536-0596, United States. Fax:
+1 859 323 8751.
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http://dx.doi.org/10.1016/j.jcf.2013.08.007are culture positive for a wide variety of bacteria, most commonly
Pseudomonas aeruginosa. Progression of the disease is charac-
terized by repeated acute bacterial flares during which an influx
of neutrophils and macrophages occurs [2], causing a decline in
pulmonary function over time [1]. Azithromycin (AZM) is a
macrolide antimicrobial agent commonly used in this patient
population for its anti-inflammatory properties. Chronic AZM
therapy improves clinical outcome measures in CF patients
including delayed lung function decline, time to acute pulmonary
exacerbation, and requirement for antimicrobial treatment [3–7].
Our previous work demonstrated that AZM polarizes macrophagesby Elsevier B.V. All rights reserved.
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type and toward the anti-inflammatory, pro-fibrotic alternatively
activated (M2) phenotype [8]. This results in decreased neut-
rophil influx and blunted pulmonary injury in mice infected
with P. aeruginosa [9]. In a previous study of 48 CF patients
that evaluated M1 and M2 polarization biomarkers, we
showed heightened expression of the M2 protein mannose
receptor (MR) on alveolar macrophages as well as an inverse
correlation between both MR expression and M2-effector
protein arginase expression as pulmonary function declines
[10]. These results suggest that M2 function has a role in
the pathophysiology of CF as the disease progresses and the
protective effect of AZM may be related to its ability to
induce M2 polarization.
Here we investigated the impact of chronic AZM therapy
and other clinical parameters including positive bacterial
culture and other antibiotics received on gene expression asso-
ciated with macrophage polarization and fibrosis development
in cells isolated from sputum samples from patients with CF.
We utilized principal component analysis (PCA) to group gene
expression values in order to describe the macrophage gene
expression signature in these patients.
2. Methods
2.1. Clinical design
The study was approved by the Institutional Review Board at
the University of KentuckyMedical Center. Patients were recruited
from the pediatric and adult CF clinics during routine visits. Pa-
tients diagnosed with CFwho were not acutely ill as determined by
the treating pulmonologist were included, although if a subject had
completed a course of therapy for an acute exacerbation, they were
eligible for inclusion. Patients were ineligible if they had a decline
in pulmonary functionmeasured as the forced expiratory volume in
one second (FEV1)% predicted compared to baseline measure-
ments or if acute antibiotic therapy was required. Additional
exclusion criteria included other active infectious processes (both
pulmonary and systemic), malnutrition, HIV infection, and cancer.
2.2. Sample collection
Subjects provided a spontaneous sputum sample during routine
clinic visits. Samples were subjected to a digestion process with the
addition of 0.1% DL-dithiothreitol (Promega, Madison, WI) plus
50 units/ml deoxyribonuclease I (Sigma Aldrich, St. Louis, MO)
to decrease viscosity. The process was repeated once if the sample
was deemed to be overly viscous. The entire sample was utilized
for later analysis, as no enrichment for macrophages was per-
formed. Cells were placed in RNAlater (Ambion, Austin, TX) and
frozen at −80 °C.
2.3. Generation of cDNA
RNA was isolated using commercially available RNeasy
Mini Kits (Qiagen, Valencia, CA) according to a standard
protocol and quantified using a NanoDrop 2000 (ThermoScientific, Wilmington, DE). Reverse transcription was per-
formed using materials from Applied Biosystems (Foster
City, CA). A set amount of isolated mRNA was incubated
with a reverse transcriptase cocktail with random hexamers.
2.4. Quantitative real-time PCR (qRT-PCR)
qRT-PCR was performed on the samples for a group of genes
that are associated with macrophage polarization, inflammatory
responses, and fibrosis using TaqMan gene probes (Applied
Biosystems, Foster City, CA). The genes for inducible nitric oxide
synthase (NOS2), Toll-like receptor 4 (TLR4), tumor necrosis
factor alpha (TNFα), interleukin (IL)-1α, IL12α, and IL12β were
selected as genes produced by the M1 phenotype in the context of
inflammation. M2 and anti-inflammatory genes selected included
arginase I (ARG1), arginase II (ARG2), chemokine (C–C motif)
ligand 18 (CCL18), MR1, IL10, and transforming growth factor
beta (TGFβ). Matrix metalloprotease 9 (MMP9), collagen 1A1
(COL1A1), and fibronectin were chosen as representative genes
for tissue remodeling. It is important to note that many of the
inflammatory and fibrotic genes are expressed in a variety of the
immune cells found in the lungs. Thus, this analysis provides a
general picture of the inflammatory and fibrotic status of the lungs
of these individuals. Samples were run in triplicate and analyzed
using an ABI 7900HT system (Applied Biosystems, Foster City,
CA). Gene expression was calculated as the relative expression
between the gene of interest and the housekeeping gene GAPDH.
2.5. Statistical analyses
PCA was performed as a method of data reduction utilizing
the statistical software package SPSS (IBM, Chicago, IL).
PCA creates a new set of uncorrelated variables comprised of
combinations of the original variables [11]. The resulting new
variables were weighted using the correlations between the
various genes. The first generated component explains the
highest amount of the total variance between the initial genes;
the second explains the next highest amount of total variance,
and so forth. Components with an eigenvalue greater than 1
were deemed to explain a significant amount of the total
variance. Additional statistical analysis was performed utili-
zing GraphPad Prism (GraphPad Software, La Jolla, CA).
Comparisons between groups were made using t-tests or the
Kruskal–Wallis test for non-parametric distributions for con-
tinuous variables and by Fisher's exact test for nominal data.
3. Results
3.1. Subject recruitment
Thirty patients were recruited for the study, with a total of 65
samples collected from September 2009 to December 2010. Of
these, 30 were original samples, and 18, 12, 4, and 1 were first,
second, third, and fourth follow-up samples, respectively, col-
lected during subsequent routine visits. While the median age
of the recruited population was 16 years (range 8–48), a
majority were under the age of 18 years (66%). A wide range of
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predicted (median of 55%, range 23–116%) and forced vital
capacity (FVC)% predicted (median of 72%, range of 33–
133%). Importantly, 76% of the cohort was chronically treated
with AZM, and 40% was being treated with other chronic
antimicrobial therapies. Among the population, 66% were culture
positive for Staphylococcus aureus and 53% for P. aeruginosa.
Age, gender, and markers of disease severity were stratified
among subjects based upon AZM treatment and positive colo-
nization with P. aeruginosa or S. aureus (Table 1). The mean age
of subjects with P. aeruginosa was significantly higher than that
of culture negative subjects, while age stratification based on
positive S. aureus cultures showed the opposite result (p = 0.052).
Positive culture for P. aeruginosa was associated with a lower
baseline FEV1% predicted and a trend toward a lower FVC%
predicted. AZM treatment status trended similarly as positive
culture for P. aeruginosa. Positive culture status for S. aureus had
no impact upon these measurements.
3.2. Effect of AZM treatment on gene expression
Fig. 1 shows an expression of genes as stratified into subsets
based upon AZM treatment from both initial and follow-up
sputum samples. Expression of the pro-inflammatory genes
TLR4, TNFα, IL1α, NOS2, and surprisingly the M2-associated
gene Arg2 was decreased in subjects receiving AZM. No
significant effects were observed in the other M2-associated
genes, although there was a trend of an increase in Col1A1
expression with AZM therapy.
3.3. Principal component analysis and gene grouping
The heterogeneous gene expression pattern in the cells
isolated suggested that a multifactorial evaluation scheme
would be more effective in classifying a molecular phenotype.
Our cohort was stratified into molecular signature subsets based
on like expression as grouped by PCA. An initial round was
performed using all 15 genes of interest from the initial sputum
samples collected from each subject (N = 30), creating 5
components. PCA requires independence among subjects,
eliminating the use of follow-up samples. An initial round of
PCA was performed to identify genes that were highly modu-
lated in different subjects. In this first round of analysis, prin-
cipal component (PC) 1 accounted for 32% of total variance of
the gene samples, while PC2 accounted for an additional 18%Table 1
Subject demographics and pulmonary function tests, stratified by azithromycin treatm
time of sampling.
Subject Demographics
Azithromycin treatment P. ae
Yes No p-Value Yes
Age (years) 20.8 15.5 0.231 23.3
Gender (percent male) 26.1 57.1 0.136 31.3
FEV1 (% predicted) 58.58 78.57 0.058 53.38
FVC (% predicted) 72.64 87.57 0.128 69.00of the total variance (data not shown). Genes weighted highly
for PC1 and low for PC2 (MMP9, NOS2, TGFβ, and TLR4)
were almost all associated with M1 or pro-inflammatory functions
(with the exception of TGFβ). Most of the genes highly weighted
in PC2 and low in PC1 (CCL18, fibronectin, IL12β, and MR1)
encode for proteins involved in alternative macrophage activation
and function (with the exception of IL12β) [12]. Gene weightings
generally grouped in a manner consistent with either anM1 or M2
activation validating the utility of this method.
A second round of PCA was performed using only genes
highly weighted in the first round of analysis. Using this restricted
gene set, 2 new components were generated that encompassed
72.4% of the total variance of the data (Fig. 2A). Components 1
and 2 again grouped the genes into similar categories as those
defined in the first round of PCA (M1- vs. M2-dominant).
For the next series of analyses, each subject was assigned a
score for PC1 and PC2 based on the sum of weighted expression
levels for all 8 biomarkers. A scatter plot generated by assigned
values for PC1 and PC2 allowed each subject to be classified into
one of 3 subsets (Fig. 2B). Set 1 was comprised of 19 subjects and
represents relatively low expression levels of the genes in the
restricted set. Set 2 was comprised of 6 subjects and represents
relatively high expression of a more inflammatory, orM1, overall
phenotype. Subset 3 was comprised of 5 subjects and represents
an overall gene expression signature that was polarized to an
M2-like profile.
Gene expression associations were confirmed through an
examination of the correlation between each pair of genes
identified from the restricted gene set (Fig. 2C). While PCA was
performed only on data from first visits, correlations were
obtained using data from initial and follow-up visits. Genes
grouped within PC1 were all highly correlated with one another,
while the genes that were grouped together in PC2 in general also
showed high levels of correlation. Exceptions included signifi-
cant correlations between MMP9 and CCL18 expression, TLR4
and CCL18 expression, and MR1 and TLR4 expression.
Comparisons were then made in individual biomarker expres-
sion when patients with CFwere grouped bymolecular phenotype.
Fig. 3 demonstrates the significant differences observed in Sets 2
and 3 compared to the expression values for the low-level gene
expression Set 1. Significantly higher expression was observed in
subjects from Set 2 for TFGβ and MMP9, with trends toward
differences between these sets in their expression of ARG2, NOS2,
and TLR4. For Set 3, significantly higher expression was
demonstrated for the M2-associated genes CCL18, fibronectin,ent status, P. aeruginosa culture positive, and S. aureus culture positive at the
ruginosa culture positive S. aureus culture positive
No p-Value Yes No p-Value
15.2 0.024 17.0 24.5 0.052
35.7 0.804 35.0 30.0 0.793
73.39 0.029 64.24 62.63 0.878
83.23 0.102 75.48 79.86 0.663
Fig. 1. Expression of M1 and M2 genes in subjects receiving AZM. Gene expression was assessed via qRT-PCR and normalized to the housekeeping gene GAPDH
(seen on the Y-axis). Mean expression values ± SD for samples obtained both from initial and follow-up visits are depicted, stratified between groups of subjects
receiving and not receiving AZM. Statistical analysis was performed using an unpaired t-test. Differences were deemed statistically significant with a p value b0.05.
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Interestingly, the pro-inflammatory cytokines TNFα and IL1α
were both significantly higher in Set 3 compared to Set 1.3.4. Correlation between molecular phenotype and clinical
characteristics
Next, we assessed the clinical characteristics of subject groups
as defined by the molecular signatures using PCA (Table 2). AZM
therapy did not influence the gene expression profile as stratified
by PCA (p = 0.422, Chi-square test). We also assessed the
bacterial infection status among our PCA-stratified subject groups.
There was no significant difference in bacterial infection between
the 3 groups for either P. aeruginosa, S. aureus, or both organisms.
Chronic, non-AZM antibiotic use was also examined among the 3
groups. While no difference was observed for treatment with
inhaled tobramycin, the use of other oral or intravenous antibiotics
was predictive of a gene signature placement into Set 1 (p = 0.027,
Chi-square test).We found that patients withM2-biased expression
displayed a trend of an increase in age as compared to the other 2
sets. There were no differences in the mean FEV1% and FVC%
predicted between the 3 groups; however, subjects in theM2-biased group were more tightly clustered around a high
FVC% predicted mean value of N77%.
4. Discussion
In this study we describe the transcriptional profile obtained
from macrophages and other cells isolated from patients with
CF. Differences in gene expression were evaluated based
upon chronic AZM therapy and other clinical parameters. As
pulmonary function gradually declines in patients with CF, a
shift to a net Th2 polarization occurs [13]. The role of the
disposition of macrophages, however, has not been clearly
defined. We have identified a number of genes expressed
primarily in macrophages which are altered in subjects treated
with AZM. Results revealed that AZM did not increase M2
polarization as much as it decreased inflammatory gene ex-
pression and genes related to M1 macrophages. Whether these
changes in expression are due primarily to the change in T cell
characteristics or other causes related to disease progression is a
topic of interest for future study. Higher level statistical ana-
lyses revealed patterns of gene expression that showed gene
expression profiles consistent with M1- or M2-polarization in
select subjects.
Fig. 2. Multifactorial analysis of restricted gene set. Factor analysis generated through evaluation of expression levels of the 8 genes analyzed from the initial sputum
samples obtained from subjects with CF as identified from the first round of principal component analysis (PCA). (A) Weighted factors for each gene are listed, along
with the eigenvalues for each component (components 1 and 2) and the amount of variance encompassed by each component. (B) Classification of individuals into
molecular phenotype subsets. Scores for components 1 and 2 were calculated for each individual based on the sum of weighted expression of all 8 genes. Set 1
includes subjects with low scores for both PC1 and PC2, Set 2 includes subjects with high PC1 scores and low PC2 scores, and Set 3 is comprised of subjects scoring
low for PC1 and high for PC2. Each point on the scatter plot represents one subject. (C) Correlation analysis of gene expression. Non-parametric evaluation was
performed using Spearman correlation analysis among genes of the restricted set generated by PCA. Correlation coefficients (r) and p-values are listed for each gene
pair comparison. Statistically significant differences (p b 0.05) are shaded.
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pro-inflammatory genes in subjects receiving AZM. There was
very little expression of NOS2 in any of the samples obtained from
subjects receiving AZM. This is consistent with our previous in
vitro and in vivo results [8–10]. NOS2 plays an important role in
the oxidative burst in M1 macrophages needed to kill internalized
microorganisms [14,15]. Excessive NOS2 gene expression can be
detrimental, especially in the context of an overly-inflammatory
M1 response [16], leading to lung damage and a decline in
pulmonary function [17]. Conversely, ARG1 and ARG2 play an
important role in tissue remodeling after an acute flare of CF and
other obstructive lung diseases [9,15,18,19]. Our data supports the
notion that at rest, the dominant impact of AZM is likely on
reducing inflammatory mediators, as a majority of the gene
expression differences were in the M1-associated subset.
The first gene grouping identified by PCA consisted of NOS2,
TLR4, TGFβ, and MMP9. NOS2 and TLR4 expression is
associated with the M1 phenotype. MMP9, a matrix meta-
lloprotease, is associated with cleavage of fibrotic proteins and is
responsible for the degradation of the extracellular matrix as part
of the tissue remodeling process. This protein has also been
previously linked to the M1 phenotype [19,20] and appears to be
up-regulated in patients with CF [21–23]. We recently publisheddata showing that AZM increases the expression of MMP9 in
both in vitro and in a mouse model of P. aeruginosa infection
[24]. These experiments, however, examined animals in the acute
phase of the response to infection, as opposed to the subjects in
this study who were not undergoing an exacerbation. MMP9may
be a key regulator in the ability of AZM to exert its protective
effects in the acute phase and is a topic of ongoing investigation.
TGFβ expression was grouped along with the genes in
component 1. Activation of TGFβ by proteases leads to
fibrogenesis [25]. Correlation with up-regulated gene expres-
sion during stable disease again may indicate that in this subset
of patients with CF, some level of tissue remodeling is taking
place. Studies have suggested that higher concentrations
of plasma TGFβ are associated with positive culture for
P. aeruginosa and worsening clinical outcomes [26]. The
placement of this gene in the M1-based component further
suggests that a bias toward the M1 phenotype may be detri-
mental. TGFβ is excreted from cells in an inactivated state and
binds to the extracellular matrix. Once a part of this matrix, it
can be cleaved into its active form by proteases including
MMP9 [25,26]. As the molecule is excreted in an inactive form,
it is difficult to correlate mRNA expression of TGFβ to the
activation of the protein.
Fig. 3. Comparison of individual biomarker groups of subjects stratified by molecular phenotype generated by multifactorial analysis of gene expression of the
restricted set as described in Fig. 2. mRNA gene expression levels were measured in the sputum samples of each subject by qPCR and normalized to expression of
GAPDH. Mean ± SEM are shown for each gene and compared by the non-parametric Kruskal–Wallis test. Asterisks indicate significant differences in gene
expression (p b 0.05) in Sets 2 and 3 as compared to that of Set 1.
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CCL18, fibronectin, IL12b, and MR genes. CCL18, fibronectin,
and MR are prominently associated with the M2 phenotype
[12,27]. In a clinical study of patients with a variety of non-CF lung
conditions, CCL18 production by cells collected by alveolar
lavage was significantly increased [28]. This was associated with
an increase in collagen production in these patients, as well as with
a shift toward an M2-dominant macrophage phenotype [29]. Our
results show that up-regulation of CCL18 corresponds to like
up-regulation in other M2-associated genes.
We sought to determine whether the differences in gene
expression signature were predictive of clinical characteristics.
Long-term AZM treatment is beneficial to those with positive
cultures for P. aeruginosa [3,5,7]. Our previous work that
suggests AZM can induce an M2-like polarization in the acute
phase of inflammation indicates that macrophage alterations are
likely involved [9,10,24]. The differences observed for positive
bacterial cultures may illustrate that a shift toward the M2
phenotype could contribute to increased susceptibility to
S. aureus or other pathogens. It is also possible that bacterial
infection may affect macrophage phenotype. Rates of subjects
with positive cultures for S. aureus and other pathogens have
been greatly increasing in subjects with CF in recent years, and
the etiology for this is unknown [30].
Our ability to correlate these patterns to clinical parameters
was on the whole unsuccessful. This could be due to the relatively
small sample size: because most subjects were receiving AZM,
comparisons based on its chronic therapy were difficult. The
amount of variability inherent in this patient population is
significant in terms of other disease complications, other drugtherapies, etc. Moreover, data generated at the gene expression
level may be inadequate, as stronger correlations were previously
established when examining protein expression in immune cells
isolated from the sputum of subjects with CF [9]. We also did not
perform differential cell counts. By doing so we would have been
able to further distinguish if gene expression that we observed
was frommacrophages, or from other immune cells in the sputum
samples. Furthermore, we did not enrich samples for macro-
phages. By not enriching the samples we believe we are getting a
better general view of the total inflammatory/fibrotic status of the
lungs of these individuals; however, by enriching collected
samples for macrophages we may have been able to see more
significant differences in markers for macrophage polarization.
Additionally, we only assessed gene expression in this project
and did not assess protein concentrations. However, we are
currently analyzing protein data in the sputum samples of these
subjects in the context of tissue remodeling. This data will show
whether the gene expression signatures then produce a protein
expression profile that is similar.
Treatment with AZM is a commonly utilized component of
cystic fibrosis therapy. This study shows that at baseline, AZM
primarily impacts pro-inflammatory gene expression, and that
the ability of AZM to polarize macrophages to an M2-like
expression pattern may be restricted to the acute inflammation
stage. Studies are ongoing to both characterize expression at the
protein level in individuals at baseline, as well as the longi-
tudinal study of gene and protein expression in subjects as they
advance in the status of their disease. It will be important to
increase our understanding of macrophage function in patients
with CF, as the ability of AZM to improve outcomes in these
Table 2
Comparison of clinical characteristics of subjects stratified by molecular phenotype. The numbers of subjects meeting each clinical criterion are listed for each
phenotypic subset as defined by multifactorial analysis (see Fig. 2). χ2 analysis tested whether each nominal clinical characteristic is predictive of molecular
phenotype. Continuous variables were compared using the Kruskal–Wallis test for non-parametric distributions. Statistical significance is for a p-value
b0.05 (shaded).
Number of Subjects
Factor Set 1 Set 2 Set 3 P
Gender
Male 7 2 1 0.505 0.777
Female 12 4 4
Azithromycin
Yes 15 4 4 0.422 0.890
No 4 2 1
P. aeruginosa
Culture positive 11 2 3 1.212 0.545
Culture negative 8 4 2
S. aureus
Culture positive 13 5 2 2.376 0.305
Culture negative 6 1 3
Co-culture positive
Yes 6 1 1 0.655 0.721
No 13 5 4
Inhaled tobramycin
Yes 7 1 1 1.170 0.557
No 12 5 4
Oral/IV antibiotics
Yes 11 1 0 7.230 0.027
No 8 5 5
Age (yrs)
Mean 19.0 15.7 26.2 0.206
SD 8.0 9.8 15.6
FEV1% Predicted
Mean 58.00 72.40 69.70 0.322
SD 23.49 28.29 24.48
FVC% Predicted
Mean 69.28 76.80 89.44 0.182
SD 22.29 31.20 13.18
χ2
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development involving effector proteins and functional aspects
of alternative macrophage activation.Acknowledgments
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